drugset / Trial / NCT06044090

Brain and Stress Study

NCT06044090

RandomizedCrossoverDouble-blindBasic science

Summary

Motivational deficits such as anhedonia are core to several psychiatric disorders and underlie significant functional impairment. This double-blind, placebo-controlled crossover trial of minocycline, an anti-\[neuro\]inflammatory agent, examines links between chronic stress and responses to a reward-related motivation task. It will evaluate the effects of pharmacologically attenuating neuroinflammation on behavioral responses to a reward-related motivation task in individuals experiencing unemployment. Understanding the effects of neuroinflammation on reward function among individuals experiencing chronic stress represents a critical first step in identifying novel neuroimmune targets for future clinical trials.

Timeline

Start
2022-09-12
Primary completion
2023-12-19
Completion
2023-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Minocycline Small molecule 200 mg Oral

Indications

No indication recorded.